Baseline characteristics and their evolution in patients who restored chronic phase MPN features during azacytidine treatment
| Patient no. . | Age, y* . | Initial MPN . | JAK2 status . | Time to progression, y . | WHO* . | Marrow blasts, %* . | Hb level at inclusion, g/L . | Plt count at inclusion, × 109/L . | Cytogenetics* . | Response . | Hb level at evaluation, g/L† . | Plt count at evaluation, × 109/L† . | Cytoreductive therapy‡ . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 60 | PV | WT | 7.8 | AML | 8§ | 8.4 | 20 | 44,XY,add(1)(q2?), del(5) (q22q33), del(7) (q22q36), −16,−17,−20,+mar[14] | CRi | 17.1 | 300 | |
| 4 | 61 | PV | V617F | 22.2 | RAEB-2 | 10 | 8.0 | 70 | 46,XX, del (20)(q11) | CR | 12.1 | 900 | IFN |
| 10 | 71 | PV | V617F | 11 | RAEB-2 | 17 | 8.8 | 147 | 46,XY[20] | CR | 17.0 | 325 | |
| 14 | 82 | ET | NA | 8.9 | AML | 34 | 8.4 | 22 | Failure | HI | 10.2 | 658 | |
| 16 | 75 | ET | NA | 14.4 | RAEB-2 | 12 | 10.1 | 478 | 47,XY, del(15)(q1?5q2?5), del(19)(p11), +21 | CR | 14.5 | 871 | BU |
| 19 | 85 | ET | V617F | 16 | RAEB-2 | 11 | 9.5 | 258 | 47,XY,+8[1]/46,XY[6] nuc ish (D8Z1x3) [30%] | CR | 10.6 | 790 | HU |
| 24 | 87 | ET | V617F | 15.3 | RAEB-1 | 7 | 9.6 | 48 | Failure | CR | 15.9 | 485 | |
| 33 | 59 | ET | WT | 2.3 | RAEB-2 | 18 | 8.0 | 135 | 45,XY, del(20)(q12)[14] | HI | 14.4 | 641 | HU |
| 44 | 61 | ET | NA | 13.8 | RAEB-1 | 8 | 9.1 | 82 | 47,XX,+8 | CR | 15.3 | 547 | |
| 48 | 81 | ET | V617F | 2.4 | RAEB-2 | 10 | 7.4 | 58 | 46,XX,del(5)(q13q33)[7]/46,sl,del(17)(p11)[9]/46,XX[3] | CR | 13.4 | 591 | HU |
| 50 | 61 | ET | V617F | 6.8 | AML | 26 | 10 | 128 | 46,XY,(1;6)(q31;q16)del(5) (q13q35),der(7;17) (p10;q10), +8,+8, der(12;18)(p11;q11), der(17)t(15;17)(q2?;q22)[20] | CR | 15.1 | 808 |
| Patient no. . | Age, y* . | Initial MPN . | JAK2 status . | Time to progression, y . | WHO* . | Marrow blasts, %* . | Hb level at inclusion, g/L . | Plt count at inclusion, × 109/L . | Cytogenetics* . | Response . | Hb level at evaluation, g/L† . | Plt count at evaluation, × 109/L† . | Cytoreductive therapy‡ . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 60 | PV | WT | 7.8 | AML | 8§ | 8.4 | 20 | 44,XY,add(1)(q2?), del(5) (q22q33), del(7) (q22q36), −16,−17,−20,+mar[14] | CRi | 17.1 | 300 | |
| 4 | 61 | PV | V617F | 22.2 | RAEB-2 | 10 | 8.0 | 70 | 46,XX, del (20)(q11) | CR | 12.1 | 900 | IFN |
| 10 | 71 | PV | V617F | 11 | RAEB-2 | 17 | 8.8 | 147 | 46,XY[20] | CR | 17.0 | 325 | |
| 14 | 82 | ET | NA | 8.9 | AML | 34 | 8.4 | 22 | Failure | HI | 10.2 | 658 | |
| 16 | 75 | ET | NA | 14.4 | RAEB-2 | 12 | 10.1 | 478 | 47,XY, del(15)(q1?5q2?5), del(19)(p11), +21 | CR | 14.5 | 871 | BU |
| 19 | 85 | ET | V617F | 16 | RAEB-2 | 11 | 9.5 | 258 | 47,XY,+8[1]/46,XY[6] nuc ish (D8Z1x3) [30%] | CR | 10.6 | 790 | HU |
| 24 | 87 | ET | V617F | 15.3 | RAEB-1 | 7 | 9.6 | 48 | Failure | CR | 15.9 | 485 | |
| 33 | 59 | ET | WT | 2.3 | RAEB-2 | 18 | 8.0 | 135 | 45,XY, del(20)(q12)[14] | HI | 14.4 | 641 | HU |
| 44 | 61 | ET | NA | 13.8 | RAEB-1 | 8 | 9.1 | 82 | 47,XX,+8 | CR | 15.3 | 547 | |
| 48 | 81 | ET | V617F | 2.4 | RAEB-2 | 10 | 7.4 | 58 | 46,XX,del(5)(q13q33)[7]/46,sl,del(17)(p11)[9]/46,XX[3] | CR | 13.4 | 591 | HU |
| 50 | 61 | ET | V617F | 6.8 | AML | 26 | 10 | 128 | 46,XY,(1;6)(q31;q16)del(5) (q13q35),der(7;17) (p10;q10), +8,+8, der(12;18)(p11;q11), der(17)t(15;17)(q2?;q22)[20] | CR | 15.1 | 808 |
MPN indicates myeloproliferative neoplasm; JAK2, Janus kinase-2; WHO, World Health Organization; Hb, hemoglobin; Plt, platelet, PV, polycythemia vera; WT, wild type; AML, acute myeloid leukemia; CRi, complete response with incomplete recovery of cytopenias; RAEB-2, refractory anemia with excess blasts 2; CR, complete response; IFN, interferon; ET, essential thrombocythemia; NA, not assessed; AML, acute myeloid leukemia; HI, hematologic improvement; BU, oral busulfan; HU, hydroxyurea; and RAEB-1, refractory anemia with excess blasts 1.
At inclusion.
At response.
After recurrence of chronic phase MPN features.
This patient was classified as AML on the basis of 31% circulating blasts.